The total number of circulating CD4+ TEM and CD8high/low TCM cells, as well as their naïve phenotypes, were reduced after alemtuzumab treatment compared to healthy controls and untreated RRMS patients (Figure 3A,B(i–iii)). The gene discussed is CD4; the disease is relapsing-remitting multiple sclerosis.